New developments in the management of prostate cancer

10Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Rapid progress was recently made in the treatment of prostate cancer, especially metastatic castration-resistant prostate cancer. At the NCCN 18th Annual Conference, Dr. Philip W. Kantoff reviewed the data supporting the use of abiraterone acetate, enzalutamide, cabazitaxel, sipuleucel-T, and radium-223 (pending approval), and offered recommendations for their sequential use in different settings. Dr. James L. Mohler described factors that dictate who should receive treatment, when they should receive it, and how to treat in the setting of prostate-specific antigen elevation. He explained how better treatment decisions will result from individualized estimation of threat-to-life posed by prostate cancer, chance of cure by treatment, and treatment risks. © JNCCN-Journal of the National Comprehensive Cancer Network.

Cite

CITATION STYLE

APA

Kantoff, P. W., & Mohler, J. L. (2013). New developments in the management of prostate cancer. In JNCCN Journal of the National Comprehensive Cancer Network (Vol. 11, pp. 653–657). Harborside Press. https://doi.org/10.6004/jnccn.2013.0194

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free